Clarius Group LLC Takes Position in bluebird bio Inc (BLUE)

Clarius Group LLC acquired a new position in shares of bluebird bio Inc (NASDAQ:BLUE) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,320 shares of the biotechnology company’s stock, valued at approximately $235,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of bluebird bio by 6.4% during the 4th quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock worth $682,366,000 after acquiring an additional 231,697 shares in the last quarter. Orbimed Advisors LLC raised its holdings in shares of bluebird bio by 20.5% during the 3rd quarter. Orbimed Advisors LLC now owns 481,946 shares of the biotechnology company’s stock worth $66,195,000 after acquiring an additional 82,146 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of bluebird bio by 32.9% during the 4th quarter. Bank of New York Mellon Corp now owns 326,446 shares of the biotechnology company’s stock worth $58,141,000 after acquiring an additional 80,883 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of bluebird bio by 11.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 296,073 shares of the biotechnology company’s stock worth $52,731,000 after acquiring an additional 29,380 shares in the last quarter. Finally, Eagle Asset Management Inc. purchased a new stake in shares of bluebird bio during the 3rd quarter worth approximately $29,539,000.

Several brokerages have recently issued reports on BLUE. Leerink Swann cut bluebird bio from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $162.00 to $194.00 in a report on Thursday, January 25th. Canaccord Genuity restated a “buy” rating and set a $250.00 price target on shares of bluebird bio in a report on Thursday, February 1st. SunTrust Banks increased their price target on bluebird bio to $223.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Wells Fargo & Co restated an “outperform” rating and set a $242.00 price target (up previously from $190.00) on shares of bluebird bio in a report on Tuesday, December 12th. Finally, BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, January 26th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $161.45.

bluebird bio Inc (NASDAQ BLUE) opened at $213.35 on Tuesday. bluebird bio Inc has a 12-month low of $73.95 and a 12-month high of $222.03.

In other bluebird bio news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the transaction, the chief operating officer now owns 13,718 shares of the company’s stock, valued at approximately $2,361,553.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nick Leschly sold 5,435 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the transaction, the chief executive officer now directly owns 171,009 shares in the company, valued at approximately $29,649,540.42. The disclosure for this sale can be found here. Insiders sold a total of 200,280 shares of company stock worth $37,818,846 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was reported by BBNS and is the sole property of of BBNS. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://baseballnewssource.com/markets/clarius-group-llc-takes-position-in-bluebird-bio-inc-blue/1892333.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.